Loading
A phase 2 trial of Nivolumab, CAPOX, Bevacizumab in colorectal cancer, run by Ono Pharmaceutical Co., Ltd., now recruiting.
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT06948448 by Ono Pharmaceutical Co., Ltd., with 144 participants planned, started 2025-11-18 and due to reach its primary completion in 2028-02-15. Interventions recorded: ONO-4578, Opdivo®, Oxaliplatin, 5-Fluorouracil, Bevacizumab. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Anti-angiogenic therapy.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Nivolumab.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Monoclonal antibodies, Colorectal cancer.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Anti-angiogenic therapy, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.